Clinical Research
Filter News
Found 135,649 articles
-
BridgeBio Pharma and its affiliate Phoenix Tissue Repair announced positive data from their Phase II clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).
-
The 25th Annual Meeting of the American Society of Gene and Cell Therapy wrapped up on Thursday. BioSpace looks at some of the highlights.
-
Fueled by $37 million in Series A financing, N.C.-based Inceptor Bio is advancing three, next-generation approaches to immuno-oncology, including a CAR-T program that is expected to be in the clinic next year.
-
A study conducted by Athersys' partner Healios on a potential treatment for ischemic stroke failed to meet the primary endpoint as its stock dropped 43%.
-
Rice University researchers used the foundation of CRISPR/Cas9 technology and developed “drive-and-process” arrays, or DAP for short.
-
Anyone who has dealt with inflammatory skin conditions is familiar with what seems like a near-constant itch. That could become a thing of the past if ASLAN Pharma has something to say about it.
-
According to researchers at the Universite Sorbonne Paris Nord, Universite Paris-Saclay, ants can be trained to sniff out the specific odors associated with certain cancers.
-
Celebrities' struggles with breast cancer are bringing new awareness to the importance of screening - particularly because new therapies like Radius Health's elacestrant are on the horizon.
-
Pancreatic transplants are difficult to pull off for Type 1 diabetes, but new technology may make it possible, and infusions of spinal fluid from young mice to older ones reportedly reverses memory loss.
-
Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
5/20/2022
Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals.
-
ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy
5/20/2022
ClearPoint Neuro, Inc. today congratulates partner PTC Therapeutics for receiving a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending its gene therapy treatment Upstaza™ (eladocagene exuparvovec),
-
Apiary Medical, Inc. Acquires Manus Medical LLC
5/20/2022
Apiary Medical, Inc. today announced the strategic acquisition of Manus Medical LLC, one of the leading SDVOSB providers of procedural packs for the federal government.
-
Clario and Cogstate Expand Partnership to Deliver Leading Data Collection and Data Quality Programs for Neuroscience Clinical Trials
5/20/2022
Collaboration combines Clario's eCOA innovations with Cogstate's expertise in neuroscience research to yield highest quality endpoints.
-
Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario
5/20/2022
Braxia Scientific Corp. a medical research company with clinics providing and advancing innovative ketamine and other innovative treatments for people living with depression and related mental health disorders.
-
Anika Receives FDA 510(k) Clearance for the X-Twist™ Knotless Fixation System, Expanding its Sports Medicine Soft Tissue PortfolioX-Twist
5/20/2022
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the X-Twist TM Knotless Fixation System.
-
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
5/20/2022
BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate company Phoenix Tissue Repair announced data from the Phase 2 trial of PTR-01, an intravenously-administered recombinant collagen 7 (rC7) protein replacement therapy, in patients with recessive dystrophic epidermolysis bullosa (RDEB).
-
Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer
5/20/2022
Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer.
-
Birmingham research brings hope for spinal cord injury treatment
5/20/2022
Scientists from the University of Birmingham have shown an existing drug may reduce damage after spinal cord injury, by blocking the inflammatory response in the spinal cord.
-
Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE Multistem Ischemic Stroke Study
5/20/2022
Athersys, Inc. announced that its partner, HEALIOS K.K., has reported topline results for its Japan ischemic stroke study, TREASURE.
-
Lipidor updates on Phase III study of AKP02 in treatment of psoriasis - half of patients now recruited
5/20/2022
Lipidor AB announces that half of the patients have now been enrolled in the Phase III study of AKP02 skin spray for mild to moderate psoriasis, with the last patient expected to begin treatment in June 2022.